• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Act sternly against those black marketing remdesivir: DGCI

|

New Delhi, July 08: India's drug controller has directed the state authorities to ensure that there is no black marketing or over-pricing of the antiviral drug remdesivir, that has been allowed under emergency use authorisation for the severely ill patients of COVID-19 disease.

Act sternly against those black marketing remdesivir: DGCI

In a letter to the state drug controllers, Drug Controller General of India, V G Somani wrote, this office has received a letter from M/s Local Circles, through ministry of health, raising concerns regarding black marketing and over pricing of the drug Remdesivir by certain unscrupulous persons.

Central drug agency warns of black marketing of COVID-19 drug Remdesivir

In view of the above, you are requested to instruct your enforcement officials to keep strict vigil on the matter to prevent black-marketing and sale of the drug Remdesivir injection above maximum retail price, he also wrote.

Further the state drug authorities have been told to take strict action against those who are found to be fleecing patients and to stop its sale immediately, if anyone is found to be selling it above the maximum price.

    Government panel to handle investigations against 3 Gandhi family trusts | Oneindia News

    The emergency authorisation allows products to be used for treatment without full data on their safety and efficacy. This is yet to be submitted as the trials continue. There also needs to be a written informed consent from those who are to be given the medicine.

    For Daily Alerts
    Get Instant News Updates
    Enable
    x
    Notification Settings X
    Time Settings
    Done
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more